Structure Therapeutics (NASDAQ:GPCR) Given Market Outperform Rating at JMP Securities

Structure Therapeutics (NASDAQ:GPCR)‘s stock had its “market outperform” rating reissued by stock analysts at JMP Securities in a report issued on Wednesday,Benzinga reports. They presently have a $91.00 price objective on the stock. JMP Securities’ price objective indicates a potential upside of 220.31% from the stock’s previous close.

Several other analysts also recently weighed in on GPCR. Cantor Fitzgerald restated an “overweight” rating and set a $65.00 price objective on shares of Structure Therapeutics in a research report on Monday, September 23rd. Morgan Stanley began coverage on shares of Structure Therapeutics in a report on Monday, September 23rd. They issued an “overweight” rating and a $118.00 target price on the stock. Finally, HC Wainwright started coverage on shares of Structure Therapeutics in a research note on Wednesday, December 4th. They set a “buy” rating and a $80.00 price target for the company. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, Structure Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $86.50.

Structure Therapeutics Stock Down 9.8 %

Shares of GPCR opened at $28.41 on Wednesday. The firm’s 50 day moving average price is $35.95 and its 200 day moving average price is $39.17. The company has a market cap of $1.63 billion, a P/E ratio of -39.59 and a beta of -3.41. Structure Therapeutics has a fifty-two week low of $28.32 and a fifty-two week high of $62.74.

Institutional Investors Weigh In On Structure Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Sandia Investment Management LP acquired a new position in shares of Structure Therapeutics during the second quarter worth $39,000. Assetmark Inc. lifted its holdings in Structure Therapeutics by 120.0% in the 3rd quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock worth $58,000 after buying an additional 719 shares in the last quarter. Quarry LP acquired a new stake in shares of Structure Therapeutics during the second quarter valued at about $79,000. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Structure Therapeutics by 60.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company’s stock worth $158,000 after acquiring an additional 1,420 shares during the last quarter. Finally, Dearborn Partners LLC acquired a new position in shares of Structure Therapeutics in the third quarter worth about $202,000. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.